Parliament Workbench
Data: Official Report to 18 Nov 2026

Official Report · Chamber

Engagements

First Minister’s Question Time

Thursday 16 May 2013 Meeting of the Parliament First Minister’s Questions 14 contributions · 3 speakers Watch on Scottish Parliament TV

Speakers

Choose an MSP to read only their contributions

The record

14 contributions
Johann Lamont Lab Glasgow Pollok
link


1. To ask the First Minister what engagements he has planned for the rest of the day. (S4F-01380)

Alex Salmond SNP The First Minister · Aberdeenshire East
link
Later today, I will be speaking with Scottish Enterprise, which is announcing that we have a record number of Scottish companies that were supported into new overseas markets last year by its international trade arm, Scottish Development International. Last year, SDI worked with 2,096 companies—a 50 per cent increase from the previous year. That is expected to lead to an increase in export sales of £880 million over the next three years.

Along with the excellent rise in job numbers yesterday, I am sure that those improving economic statistics will be welcomed by the whole Parliament. No doubt we will still have many disappointments in the future—it could not be otherwise in a recession—but those are excellent figures for the Scottish economy that we all should welcome.

Johann Lamont Lab Glasgow Pollok
link
A packet of paracetamol costs 19 pence in Tesco. To dispense it on a free prescription costs the national health service £3.10 per prescription. The NHS spends £7.2 million a year dispensing paracetamol. For that amount of money, 200 Scottish cancer patients could get cetuximab to treat their condition for free for a year. Although that treatment is free in England, Scots cancer patients have to pay about £3,000 a month for it. Does the First Minister think that that is fair?

Alex Salmond SNP The First Minister · Aberdeenshire East
link
I remind Johann Lamont that the Labour Party supported the move to free prescriptions in this chamber, in this Parliament. If it wants to reverse that policy—as many people suspect it does, in terms of the cuts commission’s deliberations—it should say clearly to the people of Scotland. In particular, it should say that to the up to 600,000 families who earn £16,000 a year or less who had to pay for prescriptions under the previous system.

The cancer drugs issue is hugely difficult and challenging. We can talk about cetuximab if Johann Lamont wishes to do so. The position, incidentally, is not as she stated.

Johann Lamont Lab Glasgow Pollok
link
Not everything in this world is an argument between the First Minister and me about manifestos—some things are more important than that. Government is precisely about the hugely challenging issues.

Scots cancer patients are three times less likely to get on the Scottish NHS the drugs that they need than are patients in England, according to cancer charities. Scottish cancer patients have to pay thousands of pounds for vital life-enhancing drugs that are available free south of the border. That means that some Scottish cancer victims are planning to uproot their families from their homes and communities to move to England for treatment that they cannot afford here. We are in danger of exporting health refugees. [Interruption.]

Members: Shame!

Tricia Marwick The Presiding Officer · Mid Fife and Glenrothes
link
Order. [Interruption.] Order.

Johann Lamont Lab Glasgow Pollok
link
I absolutely agree that it is shameful, so I am asking—[Interruption.]

Johann Lamont Lab Glasgow Pollok
link
I agree that it is shameful that we are in danger of exporting health refugees, so what is the First Minister’s advice to those families?

Alex Salmond SNP The First Minister · Aberdeenshire East
link
I will deal with the question in two ways. First, on the specific question of cetuximab, the drug was authorised by the Scottish Medicines Consortium in January 2010. The decision to restrict its use was the application from the pharmaceutical company Merck Serono Ltd. I quote from the SMC decision:

“The submitting company has requested that SMC review a niche within the licensed indication specifically for patients who had not previously received chemotherapy for their ... disease. The efficacy and safety data presented reflects this niche.”

Therefore, for that, it was approved by the SMC. It is similar to the decision that was made by the National Institute for Health and Care Excellence in England.

Of course it is the case that in England there is a cancer drugs fund to which people can apply, but cetuximab is listed in the cancer drugs fund only for specific conditions and there are restrictions on its use. We also know that the cancer drugs fund is coming to an end next year and has been heavily restricted in recent weeks.

We also know that the cancer drugs fund has been heavily criticised, including by the cancer charities that challenge the idea of the fund. We also know that the Labour Party in this Parliament voted not only to remove prescription charges from Scotland—which was a good vote—but voted against the idea of the cancer drugs fund because of the challenges to that fund. I know that Johann Lamont will not like to be reminded of this, but in tackling the extraordinarily difficult issues of access to medicine and deciding the right thing to do, if we look at the track record of the Parliament on facing up to the inequality that prescription charges imposed on the Scottish people, and on finding the right way to make available medicines that help people with life-limiting conditions, we see that the fact is that the Labour Party agreed with the Government, both on prescription charges and on our attitude to the cancer drugs fund. That puts Johann Lamont in an extraordinarily difficult position in pursuing the line of questioning that she is now pursuing.

Johann Lamont Lab Glasgow Pollok
link
The extraordinarily difficult position that I am in is that I am not able to address the problems: I can only ask the questions. I am not in government and I have a responsibility to raise the difficult issues, so I am asking the First Minister not to retreat to the comfortable refuge of party politics, but to focus on what is happening in the real world.

With respect, I say to the First Minister that what he said is not good enough for people like Maureen Fleming—a mother of three and a grandmother of 10 who has bowel cancer. Maureen has been denied the drugs that her consultant has said would improve her condition and extend her life. The Flemings are a proud family who are struggling to get together the £10,000 that is needed for the first three months’ treatment. However, they cannot afford to pay for any more treatment after that, so they are planning to leave their home of 27 years and to rent a flat in Newcastle because they can get the drug free in England. Time is short; Maureen Fleming has come to the chamber today to hear at first hand the First Minister’s advice to her and cancer victims like her.

Alex Salmond SNP The First Minister · Aberdeenshire East
link
As Johann Lamont will have noted, the review of the SMC process put forward a wide range of ways in which the SMC is effectively carrying out its job for the Scottish people. I can give Johann Lamont a list of drugs that are, because of the efficiency of the SMC process, available in Scotland but not in England.

Parliament and the cancer charities in Scotland decided that the cancer drugs fund was not the right way to go and, as we know, the cancer drugs fund in England will come to an end next year. In Scotland, we have in the Scottish Medicines Consortium an efficient process that we would be very unwise to challenge. Its effectiveness is widely admired because of the rapidity with which it judges and evaluates drugs. It is, however, capable of improvement, which is why the Routledge review was set up. We also have the individual patient treatment request system to which people can apply, according to the nature of their individual conditions. Improvements can be made to that system as well.

Johann Lamont accuses me of playing party politics, but she introduced the subject in a party political way. It is perfectly reasonable to point out that the Labour Party agreed, both on prescription charges and on our attitude to the cancer drugs fund, with our judgments on the best way in which to deliver health to the Scottish people. In the current extraordinarily difficult circumstances, we are trying to reach a position that gives the best treatment to the people of Scotland—that is the basis on which we have the SMC and the individual patient treatment request system. It is not the case that there is a simple or easy solution; we make the best judgments that we can make. That is done—as it is done, I hope, by every member—with a genuine wish to protect the welfare and health of patients in Scotland.

Johann Lamont Lab Glasgow Pollok
link
I regret that, in all that, the First Minister did not address the question that I posed to him. Mrs Fleming represents a failure in the system. While we are deliberating about how we might address the problem in the future, it is the business of Government to address what is happening now to families who do not have time to wait. We are talking about the real lives of real Scots. I will engage in the policy debate, but I urge the First Minister to act now for the people who are being failed by the system.

The First Minister and I agree that the NHS should be free at the point of need, but the reality in the First Minister’s Scotland is that if a person has a headache, their prescription is free, but if they have cancer, their prescription can cost £3,000 a month. Is not it the case that, in this Scotland, Scots with hay fever can get their prescriptions free, but Scots with cancer may have to leave their homeland for treatment to save their lives?

Alex Salmond SNP The First Minister · Aberdeenshire East
link
When this Administration abolished prescription charges, we were a minority in Parliament. If the Labour Party—and Johann Lamont—had wanted to stop that policy because they did not think that it was the right move, they could have stopped it by voting against it. In fact, they supported the policy because—I hope and believe—they felt that, for the 600,000 Scots on £16,000 a year and less, it was the right thing to do. If the Labour Party had felt that a cancer drugs fund was the right policy to have, it could have supported a cancer drugs fund in this Parliament, but it agreed with us and the cancer charities that that was not the right or proportionate thing to do.

There are always improvements that can be made to the system, but the SMC process is a robust and effective system. It is doing the absolute best that it can, and we are making improvements. The individual patient treatment request system is also a good system, which is why we are trying to standardise it across the nation by looking at particular aspects that affect individual patients.

However, to pretend to people that there is a solution to the hugely difficult questions—they are being faced by every health service around the world—about the efficacy of drugs that might be approved for use is to mislead people entirely. To pretend to people that the situation in England will continue—which it will not—or that it is satisfactory at present, is also wrong.

The last thing that I will say to Johann Lamont is that although I have every consideration and respect for the individual cases—we have all had constituents in that position, because of how things are done—we have to have regard to information from the drugs companies. Last week, a statement from Roche argued that there is the drugs tourism to which Johann Lamont referred. We should reflect on the fact that, when Avastin—the drug about which Roche was particularly concerned—came to the Scottish Medicines Consortium, Roche did not offer the discount that was asked for under the patient access scheme. That was Roche pharmaceuticals division, which has an operating profit of £10.9 billion this year. Just occasionally, in trying to overcome such difficult issues, we should perhaps ask drugs companies such as Roche why they are not prepared to offer to the Scottish people effective drugs at reasonable prices that would allow more of them to be approved.

Motions, questions and votes

Linked from this item of the Official Report
  1. General Question Time Questions · 1
  2. Antisocial Behaviour Questions · 6
  3. Schoolchildren (Additional Support Needs) Questions · 4
  4. Unscheduled Care (NHS Lanarkshire) Questions · 11
  5. Dental Services (NHS Ayrshire and Arran) Questions · 4
  6. Lands Tribunal for Scotland Questions · 5
  7. Hairpieces Contract (NHS Scotland) Questions · 8
  8. Funeral Directors (Accreditation) Questions · 4
  9. Early Years Strategy Questions · 4
  10. Engagements First Minister’s Questions · 14
  11. Secretary of State for Scotland (Meetings) First Minister’s Questions · 10
  12. Offshore Wind Energy First Minister’s Questions · 8
  13. Electronic Tagging First Minister’s Questions · 7
  14. Bullying (National Health Service) First Minister’s Questions · 6
  15. Gaelic-medium Education First Minister’s Questions · 5
  16. University Marine Biological Station Millport Members’ business · 8
  17. Electricity Market Reform Debate · 90
  18. Parliamentary Bureau Motions Business motions · 2
  19. Decision Time Decision time · 7

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.